N4 Pharma (LON:N4P) Hits New 12-Month Low – Should You Sell?

N4 Pharma Plc (LON:N4P) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as GBX 0.35 ($0.00) and last traded at GBX 0.40 ($0.01), with a volume of 2285468 shares traded. The stock had previously closed at GBX 0.38 ($0.00).

N4 Pharma Stock Up 6.7 %

The firm has a market cap of £1.72 million, a price-to-earnings ratio of -1.16 and a beta of -0.37. The company has a 50 day moving average of GBX 0.51 and a 200 day moving average of GBX 0.59.

About N4 Pharma

N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.